Acrivon Therapeutics Inc. (ACRV)
NASDAQ: ACRVHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ACRV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $80.14M
- EPS (TTM)
- -$1.88
- Dividend yield
- None
- 52-week range
- 1.27 – 3.56
- Day range
- 1.78 – 1.91
- Volume / Avg
- 419.16K / 361.40K
- Beta
- —
- Shares outstanding
- 42.85M
52-week range
ACRV stock today
On Oct 8, ACRV ended the session at $1.87, shedding $0.01 (0.53%), versus the S&P 500's 0.47% decline. At this level, ACRV sits in the middle of its 52-week range of $1.27 to $3.56: 47.5% below the high, set on Jan 7, 2026 and 47.2% above the low. ACRV is down 22.4% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 0.5%.
Acrivon Therapeutics has posted a net loss over the last twelve months (EPS of -$1.88), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Acrivon Therapeutics
Company profileAcrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Peter Blume-Jensen M.D., Ph.D.
- Headquarters
- Watertown, MA
- Employees
- 74
- IPO year
- 2022
- Website
- acrivon.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$11.50+514.97%
- Strong buy 3
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Acrivon Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PMNProMIS Neurosciences Inc. | 9.15 | +0.33% | $82.05M | vs ACRV |
| CRDFCardiff Oncology Inc. | 1.06 | -2.75% | $82.46M | vs ACRV |
| PTHSPelthos Therapeutics Inc. | 20.50 | -2.33% | $78.48M | vs ACRV |
| TELOTelomir Pharmaceuticals Inc. | 1.15 | +2.68% | $84.66M | vs ACRV |
| NRXSNeuraxis Inc. | 6.77 | -0.88% | $85.02M | vs ACRV |
| CGTXCognition Therapeutics Inc. | 0.8952 | -4.42% | $85.13M | vs ACRV |
| OSTXOS Therapies Incorporated | 1.62 | +4.52% | $75.82M | vs ACRV |
| MNOVMedicinova Inc | 1.54 | -4.35% | $75.80M | vs ACRV |
Indexes, lists and sector
Appears in lists
Acrivon Therapeutics stock FAQ
What is Acrivon Therapeutics's stock price today?
ACRV last traded at $1.87 as of Oct 8, 4:00 PM EDT, down 0.53% on the day. Prices are delayed at least 15 minutes.
Who is Acrivon Therapeutics's CEO?
Dr. Peter Blume-Jensen M.D., Ph.D. is the chief executive officer of Acrivon Therapeutics Inc., which has about 74 employees.
What is the ACRV 52-week high?
The 52-week high for ACRV is $3.56 and the 52-week low is $1.27. The stock is currently 47.5% below its high.